NDAORAL-21TABLET
Approved
Dec 1981
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Data completeness
2/8 — Basic
DEMULEN 1/35-21 (ethinyl estradiol; ethynodiol diacetate) by Pfizer. Approved for pregnancy. First approved in 1981.
Drug data last refreshed 23h ago · AI intelligence enriched 3d ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
DEMULEN 1/35-21 is an oral contraceptive combining ethinyl estradiol (estrogen) and ethynodiol diacetate (progestin) in a 21-day tablet regimen. It prevents pregnancy by suppressing ovulation and altering cervical mucus. This product represents a legacy oral contraceptive from the 1981 approval era, now facing significant lifecycle pressure.
LOE Approaching
Declining market share and approaching loss of exclusivity signal reduced team investment and limited promotional headcount growth.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications (1)
Career Relevance
Working on DEMULEN 1/35-21 offers limited career growth opportunity given LOE trajectory and zero linked job postings. Roles emphasize defensive commercial management, reimbursement preservation, and managed market strategy rather than brand building or innovation.
Brand Manager
Worked on DEMULEN 1/35-21 at Pfizer? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.